Company intelligence / Profile preview

G-Nanosystems

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

G-Nanosystems is a South Korean biotechnology company specializing in advanced drug delivery systems, particularly lipid nanoparticles (LNPs) for mRNA-based therapeutics and vaccines. Founded by Professor Sung-Joo Hwang of Seoul National University, the company leverages its proprietary G-LNP platform to overcome challenges in mRNA stability and delivery efficiency. G-Nanosystems focuses on developing next-generation mRNA vaccines for infectious diseases and cancer immunotherapies. The company's technology aims to provide high encapsulation efficiency and targeted delivery with reduced toxicity.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapySmall interfering RNA
Industry: Biotech

Drug pipeline

1 asset

NPC12-G

Preclinical

Partnerships

Seoul National University

Beyond the preview

Go deeper on G-Nanosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-Nanosystems.

Explore the full profile